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US researchers are grappling with
the issue of human embryonic
stem cell research, in the face of
severe restrictions in federal
funding and lobby groups
opposed to it. But California is
forging ahead, following the
November vote that gave support
to an ambitious plan over the next
ten years.
Bolstering their plans, Robert
Dynes, president of the
University of California, is due to
arrive in Britain next month to
meet alumni and other key
researchers on plans to create
and fund the new stem cell
research centre.
Dynes, who is credited with
turning Arnold Schwarzenegger,
the governor of California, on to
science, told reporters he was
hoping to ‘sniff out’ talent.
“I’d be interested in 28-year-
olds and big names too; you need
to take the whole spectrum. We
want people with a really good
idea that is off the wall.”
A major conference is planned
next month in Anaheim to discuss
stem cell research and bolster the
state’s plans.
George W. Bush’s
administration opposes human
embryonic stem cell research,
but last November Californians
broke away and voted for a state
initiative known as Proposition
71, which committed $3 billion
over ten years to stem cell
research.
Dynes hopes this financial
backing will put California at the
forefront of stem cell research
globally. But he stressed that
research cash and impressive
facilities would not be the only
benefits for researchers who
chose to relocate. “What I will do
is tell young researchers that
California is the most innovative,
diverse and risk-taking society in
the world,” he said.
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While other states consider their position on the controversial issue of
human embryonic stem cell research, California is forging ahead with a
major scientific meeting planned for May and recruitment of overseas
researchers for its new institute. Nigel Williams reports.
Points ahead: California is taking the lead on human embryonic stem cell research in the US in the face of federal restrictions on
what work can be funded. Plans for a new institute are well advanced and the president of the University of California is planning a
trip abroad next month to help recruit scientists. (Picture: Science Photo Library.) 
Zach W. Hall, a neurobiologist
and veteran administrator at the
National Institutes of Health and
two California medical schools,
was recommended to run the
state’s new stem cell institute, as
the interim president of the
California Institute for
Regenerative Medicine.
A nationwide search is on for a
full-time president of the institute
who will be responsible for hiring
staff and implementing policies
for a precedent-setting new state
agency that is being watched by
other states and countries.
The creation of the institute
got the go-ahead in November,
when California voters backed
the plans.
Since July 2002, Hall has been
medical research dean at the
University of Southern California.
He was executive vice-
chancellor at the University of
California San Francisco from
1997 to 2001. As part of that job
he was responsible for planning
the 43 acre Mission Bay campus
in San Francisco, part of a
300 acre public/private
biomedical research park.
California’s efforts to surge
ahead on stem cell research
have forced other states to
consider their position. Many
fear they may lose key
researchers who may decide to
head west to pursue their
research and are therefore
scratching their heads about
state-level responses. In New
York, state lawmakers proposed
spending at least $100 million a
year for stem cell research,
joining a growing number of
states seeking to fill the void left
by the federal ban on funding to
expand the studies. They fear
that New York is in danger of
losing top scientists to states
willing to fund it.
“We know they are actively
being recruited,” said Maria
Mitchell, president of the
Academic Medicine
Development Company, which
represents medical schools and
research institutes.
In Maryland, efforts are also
under way to provide funds for
stem cell research. But
opposition to such proposals has
prompted changes suggested by
two Democratic sponsors that
would limit state funding for
research on embryos that
already exist. But such a move is
unlikely to allay concerns from
those with religious and ethical
objections.
The proposed Maryland bill
would funnel $25 million a year
to stem cell research. In
committee hearings held earlier
this month, Senator Paula C.
Hollinger and Delegate Samuel I.
Rosenberg said they intended to
change the bill to fund only
embryonic research conducted
on embryos left over at fertility
clinics. The bill would exclude
funding where embryos are
created specifically for research,
a process commonly referred to
as therapeutic cloning.
Hollinger, chairwoman of the
education, health and
environmental affairs committee,
and Rosenberg said they hoped
the change would ease the
passage of the bill and increase
the likelihood of support from
Governor Robert L. Ehrlich, who
has taken no position on the
legislation. “The fact is, why
would somebody prefer having
these embryos discarded in a
trash can when they could be
helping real human beings?” said
Hollinger. “There’s only so much
money, so there’s no reason why
it shouldn’t be limited to an area
where everyone can be
comfortable.”
The Rosenberg and Hollinger
bill would use money from the
state’s tobacco settlement to
provide $25 million a year to
private and public institutions
conducting stem cell research,
with preference given to
proposals not eligible for federal
funding, starting in 2007. The
Johns Hopkins University and
the University of Maryland, which
conduct the bulk of stem cell
research in the state, are not
taking a position on the bill as
institutions. Several researchers
from Johns Hopkins, however,
will testify to support it.
Members of Families for Stem
Cell Research, a state-wide
coalition formed to lobby for the
bill, said that, although they
preferred the original legislation,
they will back whatever support
the state can give. “I would
prefer it to be more inclusive
because I would like to see all of
the research explored,” said
Margaret Conn Himelfarb of
Baltimore, who is spearheading
the coalition. “But I think it is
important to proceed.”
Curt I. Civin, a professor of
cancer research at Hopkins’
Kimmel Cancer Center who
conducts stem cell research, said
it helps those like him who are
looking for support for what they
believe could be ground-breaking
research. “It doesn’t equal
California, but it is halfway there
and I think that’s good,” he said.
Meanwhile in Massachusetts,
researchers have been
concerned by comments of the
governor, Mitt Romney, after he
declared in a published interview
that he favoured banning the
creation of new human embryos
for the purposes of research,
seen as an attack on work being
planned at Harvard University
and the basis of original plans for
work in Maryland.
The governor’s remarks
prompted the provost of Harvard
to complain in an interview that
Massachusetts could lose
ground in the competition that
has erupted among scientists,
politicians and private
companies since California
voters passed the $3 billion
initiative for stem cell research.
But in spite of California’s
ambitions, there is still some
local opposition. Conservative
public-interest groups with ties
to Christian organizations have
filed lawsuits last month seeking
to invalidate the $3 billion stem
cell research commitment.
One of the lawsuits alleges
that the California Institute for
Regenerative Medicine violates
state law because it’s not
governed exclusively by the state
government and the committee
that controls the research money
it will allocate isn’t publicly
elected.
So Californian researchers may
yet still get a little of what other
states are encountering in the
balancing act between research
goals and perceived therapeutic
opportunities and some sectors
of public opinion.
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